The Claim

In mice fed a high-fat diet, treatment with GW501516 is associated with increased levels of nuclear lipin 1 protein in hepatocytes, which may contribute to enhanced regulation of fatty acid metabolism via coactivation of PPARα signaling.

Source: The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
12score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

In mice on a high-fat diet, a drug called GW501516 might help liver cells better manage fat by turning up a key protein and activating a fat-burning switch.

See the scientific wording

In mice consuming a high-fat diet, GW501516 treatment is associated with increased nuclear lipin 1 protein levels in hepatocytes, which may contribute to enhanced regulation of fatty acid metabolism through coactivation of PPARα signaling.

What the research says

1 study

  1. Study: The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

    The study shows that the drug GW501516 increases a key protein in liver cells that helps burn fat more efficiently in mice on a high-fat diet, which is exactly what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.